<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="iso-abbrev">Clin Cancer Res</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Clinical cancer research : an official journal of the American Association for Cancer Research</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">1078-0432</issn>
        <issn pub-type="epub">1557-3265</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC11233068</article-id>
        <article-id pub-id-type="pmcid-ver">PMC11233068.319</article-id>
        <article-id pub-id-type="pmcaid">11233068</article-id>
        <article-id pub-id-type="pmcaiid">11233068</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS1931569</article-id>
        <article-id pub-id-type="pmid">37682528</article-id>
        <article-id pub-id-type="doi">10.1158/1078-0432.CCR-23-1283</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS1931569</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA1931569</article-id>
        <article-version article-version-type="pmc-version">319</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Guercio</surname>
              <given-names initials="BJ">Brendan J.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A2" ref-type="aff">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sarfaty</surname>
              <given-names initials="M">Michal</given-names>
            </name>
            <xref rid="A3" ref-type="aff">3</xref>
            <xref rid="A4" ref-type="aff">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Teo</surname>
              <given-names initials="MY">Min Yuen</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A5" ref-type="aff">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ratna</surname>
              <given-names initials="N">Neha</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Duzgol</surname>
              <given-names initials="C">Cihan</given-names>
            </name>
            <xref rid="A6" ref-type="aff">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Funt</surname>
              <given-names initials="SA">Samuel A.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A5" ref-type="aff">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lee</surname>
              <given-names initials="CH">Chung-Han</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A5" ref-type="aff">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Aggen</surname>
              <given-names initials="DH">David H.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A5" ref-type="aff">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Regazzi</surname>
              <given-names initials="AM">Ashley M.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chen</surname>
              <given-names initials="Z">Ziyu</given-names>
            </name>
            <xref rid="A7" ref-type="aff">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lattanzi</surname>
              <given-names initials="M">Michael</given-names>
            </name>
            <xref rid="A8" ref-type="aff">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Al-Ahmadie</surname>
              <given-names initials="HA">Hikmat A.</given-names>
            </name>
            <xref rid="A9" ref-type="aff">9</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Brannon</surname>
              <given-names initials="AR">A. Rose</given-names>
            </name>
            <xref rid="A7" ref-type="aff">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Shah</surname>
              <given-names initials="R">Ronak</given-names>
            </name>
            <xref rid="A7" ref-type="aff">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chu</surname>
              <given-names initials="C">Carissa</given-names>
            </name>
            <xref rid="A10" ref-type="aff">10</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lenis</surname>
              <given-names initials="AT">Andrew T.</given-names>
            </name>
            <xref rid="A11" ref-type="aff">11</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Pietzak</surname>
              <given-names initials="E">Eugene</given-names>
            </name>
            <xref rid="A5" ref-type="aff">5</xref>
            <xref rid="A10" ref-type="aff">10</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bochner</surname>
              <given-names initials="BH">Bernard H.</given-names>
            </name>
            <xref rid="A5" ref-type="aff">5</xref>
            <xref rid="A10" ref-type="aff">10</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Berger</surname>
              <given-names initials="MF">Michael F.</given-names>
            </name>
            <xref rid="A7" ref-type="aff">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Solit</surname>
              <given-names initials="DB">David B.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A5" ref-type="aff">5</xref>
            <xref rid="A7" ref-type="aff">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Rosenberg</surname>
              <given-names initials="JE">Jonathan E.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A5" ref-type="aff">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bajorin</surname>
              <given-names initials="DF">Dean F.</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A5" ref-type="aff">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Iyer</surname>
              <given-names initials="G">Gopa</given-names>
            </name>
            <xref rid="A1" ref-type="aff">1</xref>
            <xref rid="A5" ref-type="aff">5</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>1</label>Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A2"><label>2</label>Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY</aff>
        <aff id="A3"><label>3</label>Institute of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel</aff>
        <aff id="A4"><label>4</label>Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel</aff>
        <aff id="A5"><label>5</label>Weill Cornell Medical College, New York, NY</aff>
        <aff id="A6"><label>6</label>Commonwealth Radiology Associates, Andover, MA</aff>
        <aff id="A7"><label>7</label>Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A8"><label>8</label>Texas Oncology, Austin, TX</aff>
        <aff id="A9"><label>9</label>Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A10"><label>10</label>Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY</aff>
        <aff id="A11"><label>11</label>Department of Urology, Columbia University Irving Medical Center, New York, NY</aff>
        <author-notes>
          <corresp id="CR1"><bold>Corresponding author:</bold> Gopa Iyer, MD, 300 East 66<sup>th</sup> St, BAIC 1249, New York, NY 10065, <email>iyerg@mskcc.org</email>, Fax: 646-227-2417</corresp>
          <fn fn-type="COI-statement" id="FN1">
            <p id="P63"><bold>Conflicts of Interest:</bold> B. Guercio reports honoraria from Medscape; institutional research funding from Oncocyte and Genentech; as well as expenses from Seagen/Astellas, EMD Serono, Natera, Gilead, Aveo Oncology, and Exelixis. M. Sarfaty reports honoraria from Pfizer, Bristol Myers Squibb/Pfizer, Janssen, Astellas Pharma, Astellas Pharma, MSD Oncology, MSD Oncology; consulting or advisory role with Astellas Pharma and MSD Oncology; as well as institutional research funding from AstraZeneca. M.Y. Teo reports consulting/advisory role for Janssen Oncology and institutional research funding from Bristol-Myers Squibb, Clovis Oncology, and Pharmacyclics. S.A. Funt reports employment with ByHeart; stock and other ownership interests in Kite, a Gilead company, UroGen pharma, Allogene Therapeutics, Neogene Therapeutics, Kronos Bio, Vida Ventures, IconOVir Bio, and Doximity, 76Bio; consulting or advisory roles with Merck, Immunai, and BioNTech; institutional research funding from Genentech/Roche, AstraZeneca, Decibel Therapeutics; as well as travel, accommodations, or expenses from Bristol Myers Squibb, and AstraZeneca/MedImmune. C.H. Lee reports honoraria from Intellisphere, Research to Practice, and American Institute of Continuing Medical Education; consulting or advisory role for Bristol Myers Squibb, Eisai, EMD Serono, Exelixis, Merck, and Pfizer; as well as institutional research funding from Bristol Myers Squibb, Calithera Biosciences, Eisai, Eli Lilly, Exelixis, Merck, and Pfizer. D.H. Aggen reports research funds from Seattle Genetics and Astellas. M. Lattanzi reports consulting with Janssen, Aveo, Merck, Aadi; and speaking fees from Seagen, Janssen, Astrazeneca, EMD Serono. H.A. Al-Ahmadie has provided consultation to AstraZeneca, Janssen Biotech, Bristol-Myers-Squibb, and Paige.ai. E. Pietzak reports honoraria from UpToDate; consulting or advisory roles with Merck, Chugai Pharma, QED Therapeutics, Janssen, and Urogen pharma; as well as research funding from Janssen. B.H. Bochner reports consulting or advisory role for Olympus. M.F. Berger reports a patent pending on “Systems and Methods for Detecting Cancer Via cfDNA Screening;” research funding from Grail; consulting fees from Eli Lilly and PetDx. L.D.E.: and is an employee of and shareholder in Puma Biotechnology, Inc. D.B. Solit has served as a consultant for/received honorarium from Pfizer, Loxo/Lilly Oncology, Vividion Therapeutics, Scorpion Therapeutics, Fore Therapeutics, FOG Pharma, Rain Therapeutics, and BridgeBio. J.E. Rosenberg has served as a consultant for Astellas, Seagen, Merck, Roche, Genentech, AstraZeneca, Janssen Biotech, Gilead, Pfizer, EMD-Serono, Mirati, Boehringer Ingelheim, Pharmacyclis, GSK, Infinity, Tyra BioSciences, Bayer, and QED Therapeutics and received honoraria from EMD-Serono. D.F. Bajorin reports honoraria from Bristol Myers Squibb/Medarex; consulting or advisory roles with Merck, Bristol Myers Squibb Foundation; as well as institutional research funding from Novartis, Merck, Bristol Myers Squibb, AstraZeneca, Astellas Pharma, and Seattle Genetics/Astellas. G. Iyer reports consulting or advisory roles with Bayer, Janssen, Mirati Therapeutics, Basilea, Flare Therapeutics, and Loxo/Lilly; speakers’ bureau activities with Gilead Sciences and Lynx Group; as well as institutional research funding from Mirati Therapeutics, Novartis, Debiopharm Group, Bayer, Janssen, and Seattle Genetics. N. Ratna, C. Duzgol, A.M. Regazzi, Z. Chen, A.R. Brannon, R. Shah, C. Chu, A.T. Lenis declare no potential conflicts of interest.</p>
          </fn>
        </author-notes>
        <pub-date pub-type="ppub">
          <day>14</day>
          <month>11</month>
          <year>2023</year>
        </pub-date>
        <volume>29</volume>
        <issue>22</issue>
        <issue-id pub-id-type="pmc-issue-id">466338</issue-id>
        <fpage>4586</fpage>
        <lpage>4595</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>27</day>
              <month>06</month>
              <year>2024</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>09</day>
              <month>07</month>
              <year>2024</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>09</day>
              <month>07</month>
              <year>2024</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2024-07-11 09:25:14.620">
              <day>11</day>
              <month>07</month>
              <year>2024</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1931569.pdf"/>
        <abstract id="ABS1">
          <sec id="S1">
            <title>Purpose:</title>
            <p id="P1">Erdafitinib is the only FDA-approved targeted therapy for FGFR2/3-altered metastatic urothelial cancer. We characterized the genetic landscape of FGFR-altered urothelial carcinoma and real-world clinical outcomes with erdafitinib, including on-treatment genomic evolution.</p>
          </sec>
          <sec id="S2">
            <title>Methods:</title>
            <p id="P2">Prospectively collected clinical data were integrated with institutional genomic data to define the landscape of FGFR2/3-altered urothelial carcinoma. To identify mechanisms of erdafitinib resistance, a subset of patients underwent prospective cell-free (cf)DNA assessment.</p>
          </sec>
          <sec id="S3">
            <title>Results:</title>
            <p id="P3">FGFR3 alterations predictive of erdafitinib sensitivity were identified in 39% (199/504) of patients with non-muscle invasive, 14% (75/526) with muscle-invasive, 43% (81/187) with localized upper tract, and 26% (59/228) with metastatic specimens. One patient had a potentially sensitizing FGFR2 fusion. Among 27 FGFR3-altered cases with a primary tumor and metachronous metastasis, 7 paired specimens (26%) displayed discordant FGFR3 status. Erdafitinib achieved a response rate of 40% but median progression-free and overall survival of only 2.8 and 6.6 months, respectively (n = 32). Dose reductions (38%, 12/32) and interruptions (50%, 16/32) were common. Putative resistance mutations detected in cfDNA involved TP53 (n=5), AKT1 (n=1), and second-site FGFR3 mutations (n=2).</p>
          </sec>
          <sec id="S4">
            <title>Conclusion:</title>
            <p id="P4">FGFR3 mutations are common in urothelial carcinoma, whereas FGFR2 alterations are rare. Discordance of FGFR3 mutational status between primary and metastatic tumors occurs frequently and raises concern over sequencing archival primary tumors to guide patient selection for erdafitinib therapy. Erdafitinib responses were typically brief and dosing was limited by toxicity. FGFR3, AKT1, and TP53 mutations detected in cfDNA represent putative mechanisms of acquired erdafitinib resistance.</p>
          </sec>
        </abstract>
        <kwd-group>
          <kwd>erdafitinib</kwd>
          <kwd>FGFR</kwd>
          <kwd>urothelial carcinoma</kwd>
          <kwd>bladder cancer</kwd>
          <kwd>cell-free DNA</kwd>
        </kwd-group>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
